CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Joshua Ofman

Chief Executive Officer, GRAIL, Inc.

Search every verified Joshua Ofman interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Joshua Ofman, president of GRAIL, has been promoting the company’s Galleri multi-cancer early detection (MCED) test, which uses a blood draw to detect DNA methylation signals associated with more than 50 types of cancer. In interviews and presentations from 2021 to 2026, Ofman described the test as a complement to standard screenings for individual cancers, stating that it can identify cancers not covered by existing screening protocols and that it may help detect aggressive tumors at earlier stages. He cited company-published estimates suggesting that adding Galleri to standard screening could intercept a large share of cancers and reduce cancer mortality, while also acknowledging limitations such as the test’s inability to detect all cancers and its cost. Ofman has also discussed the challenges of bringing the test to broader populations, including the need for FDA approval, Medicare coverage, and commercial payer reimbursement. He has argued that current screening approaches miss many cancers and generate false positives, and he has called for accelerated coverage decisions for novel technologies. In his public remarks, he has emphasized the role of genomics and machine learning in cancer detection and has framed the test as part of a shift toward screening for multiple cancers at once rather than one at a time.

Recent appearances

  • Capturing Cancer Signals to Aid Early Detection - Dr. Josh Ofman, President of GRAIL

    August 12, 2026 · 📺 Osmosis from Elsevier

    The value of early detection is perhaps greater for cancer than many other diseases because it remains the second leading cause of death worldwide. On this episode of Raise the Line we're going to learn about a new testing approach that leverages genomic technology and machine learning to detect signals circulating in the blood across more than 50 types of cancers -- far beyond the number currently screened for -- and helps physicians target locations for diagnostic evaluation. “We can look at this epigenetic pattern on very specific regions of the DNA and say this is only seen in cancer, and…

    Watch on YouTube ↗

  • GRAIL President Discusses Gaps and Opportunities in Cancer Care

    October 18, 2025 · 📺 GRAIL

    Despite advances in cancer care, critical gaps remain, and many cancers still go undetected until it's too late. Hear Josh Ofman, MD, MSHS, President of GRAIL, explain how the Galleri multi-cancer early detection (MCED) test can detect more than 50 types of cancer before symptoms appear[1] – when there may be more treatment options available.[2,3] Learn more: http://galleri.com http://grail.com Galleri should be used in addition to healthcare provider recommended screening tests. The Galleri test does not detect a signal for all cancers, and not all cancers can be detected in the blood. Fal…

    Watch on YouTube ↗

  • Early Detection Saves Lives | The Promise of Multi-Cancer Screening with Dr. Josh Ofman

    October 03, 2024 · 📺 Medicine for Good

    In this episode, we explore a groundbreaking leap in cancer detection—one that may save millions of lives through early screening. Imagine a world where a single blood test could detect over 50 types of cancer, including those that are often diagnosed too late, like pancreatic, ovarian, and lung cancers. The Gallery Test, developed by GRAIL, offers a revolutionary approach to identifying cancer in its earliest stages when treatment is most effective. Dr. Gabiola, who tragically lost her husband to pancreatic cancer at just 46, takes us through her deeply personal connection to this issue. She…

    Watch on YouTube ↗

  • The Dawn of a New Era in Cancer Screening - Dr. Josh Ofman | 1149 | Dave Asprey

    April 02, 2024 · 📺 Dave Asprey

    What if you could catch cancer in its earliest stages, when it's most treatable—would you seize that chance? Our guest today is Dr. Josh Ofman, the president of GRAIL, and he's pioneering early cancer detection in a revolutionary new way. You'll discover the cutting-edge advances in multi-cancer early detection that are transforming the fight against this swift and silent killer. You'll also learn about the full potential of the GRAIL gallery test in your proactive health management. This technology is ushering in a new era in cancer care but also signals a paradigm shift in disease prevention…

    Watch on YouTube ↗

  • Grail's Josh Ofman on the Revolution of Cancer Screening [Episode 104]

    January 03, 2023 · 📺 The Harry Glorikian Show

    Out of all the dozens of types of cancer that occur in humans, we habitually screen for only five: breast, cervical, colon, prostate, and lung. But what if there were a single test that could detect 50 types of cancer, based on a simple blood draw? That's exactly what's possible today, thanks to the Galleri test, introduced by Illumina spinoff Grail in 2021. The $949 test, which won breakthrough designation from the FDA in 2019, uses machine learning to assess the patterns of methyl groups—molecules that attach to chromosomes and control gene activity—in free-floating DNA shed by tumors. Thi…

    Watch on YouTube ↗

  • MCED Technology & Improving Cancer Detection in the Population - Joshua Ofman, GRAIL

    July 14, 2021 · 📺 Prevent Cancer Foundation

    MCED Technology & Improving Cancer Detection in the Population Joshua Ofman, MD, Chief Medical Officer and Head of External Affairs, GRAIL Learn more about Multi-Cancer Early Detection (MCED) at https://www.preventcancer.org/early

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →